Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Recombinant allergens for immunotherapy.

Rudolf Valenta1, Verena Niederberger

  • 1Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria. rudolf.valenta@meduniwien.ac.at

The Journal of Allergy and Clinical Immunology
|March 6, 2007

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Engineering
  • Materials Engineering
  • Wearable Materials
  • Recombinant Allergens For Immunotherapy.

    • Recombinant allergens offer consistent quality for allergy diagnostics and therapeutics. Clinical trials show recombinant allergen immunotherapy is effective and may lead to new treatment strategies.

    Area of Science:

    • Biotechnology
    • Immunology
    • Allergy Research

    Background:

    • Recombinant allergens provide defined molecules with consistent quality and quantity.
    • Allergen modification can reduce IgE-mediated side effects and enhance immunologic properties.
    • Recombinant allergens are valuable for both diagnostic and therapeutic applications in allergy.

    Purpose of the Study:

    • To evaluate the efficacy and vaccination characteristics of recombinant allergen-based immunotherapy.
    • To explore the potential of modified recombinant allergens for improved immunotherapy.
    • To assess the promise of recombinant allergens for new treatment strategies and prophylactic vaccination.

    Main Methods:

    • Production of recombinant allergens using DNA templates.
    • Modification of recombinant allergens to reduce allergenicity and improve immunologic properties.
    • Conducting injection immunotherapy trials with recombinant vaccines for pollen allergies.

    Main Results:

    • Recombinant allergen-based immunotherapy demonstrated effective vaccination characteristics in clinical trials.
    • Recombinant allergen immunotherapy proved clinically effective in treating birch and grass pollen allergies.
    • The study confirmed the feasibility and efficacy of using recombinant allergens in immunotherapy.

    Conclusions:

    • Recombinant allergen immunotherapy is a clinically effective treatment option.
    • Recombinant allergens hold significant promise for advancing current immunotherapy practices.
    • Future applications may include novel treatment strategies and prophylactic allergy vaccination.

    Related Experiment Videos